2. Olapareb: Adverse Events and QOL in BRCA

Because many clinical papers include adverse events as a table, I wanted to translate this type of data into a more visually digestible format that would be quickly interpreted. 

Table S4 in the 2019 OlympiAD trial publication reported the tolerability results for the poly (ADP-ribose) polymerase (PARP) inhibitor LYNPARZA® (olaparib) in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. I focused only the AE data for the visual, choosing not to translate the entire paper in this first step. Since the intent of the graphic is a replacement for the original tabular data and since the target audience is assumed to be the readership of this research, I excluded additional text descriptions of the data.

I imported this data into Tableau and created a simple interactive bar graph that shows the chemotherapy treatment of physician’s choice (TPC) as a target mark line over the main bar for the Olaparib AE. The contrasting orange color of over blue allows the viewer to quickly assess which AE was greater for each arm of the study. Rollovers provide the percentage data found in the table for quick reference.